Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Shift Work

Chronic Circadian Disruption

Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.

0 human trials, about 1000 studies, >1,000,000 participants (epidemiology). The written rationale for this grade is still being prepared.

FDA
IARC Group 2A (probable carcinogen)
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

The health associations are serious and appear cumulative with years worked, spanning cardiometabolic disease, mood, and a probable (not proven) cancer signal. Harm-reduction measures such as strategic light exposure, anchor sleep, and meal timing may help but do not eliminate the risk of chronic circadian disruption. Persistent excessive sleepiness, insomnia tied to a shift schedule, or a personal or family history of cardiovascular disease, diabetes, depression, or cancer warrants evaluation by a qualified sleep-medicine or occupational-health provider, who can assess for Shift Work Disorder and individualize care; this entry is educational and is not medical advice or a treatment protocol.

Shift work, especially night and rotating schedules, is the most studied real-world model of chronic circadian disruption, and IARC classifies night shift work as a Group 2A probable human carcinogen. Roughly 3 to 13 percent of workers do night-specific work and 16 to 27 percent do some shift work, exposing a very large population. The cardiometabolic associations are the most consistent: large meta-analyses link shift work to coronary heart disease and myocardial infarction (relative risk near 1.2) and to type 2 diabetes (near 1.1, rising with years worked), with depression and obesity also signaled. The cancer evidence is real but more contested, with the breast-cancer association in particular disputed between IARC and a large prospective pooling. A clinical diagnosis, Shift Work Disorder, is recognized in the ICSD-3, and a qualified sleep or occupational-health provider should guide any individual case.

Classified a probable carcinogen. The most serious, most overlooked circadian harm.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Understanding occupational circadian risk as the best-studied real-world model of chronic disruption
  • Framing harm-reduction strategies for shift workers (strategic light timing, anchor sleep, meal timing, daytime light protection)
  • Informing public-health, scheduling, and occupational-safety policy
  • Recognizing Shift Work Disorder as a diagnosable condition warranting clinical evaluation
  • Contextualizing why the wellness industry underserves a very large, clearly at-risk population

What people get wrong

  • Often saidYou just get used to night shifts after a while

    ActuallyControlled studies show only a small minority of night workers ever fully circadian-adapt, because daytime light on the commute home keeps resetting the clock. Most remain chronically misaligned, which is why the associated health signals persist over years (Boivin et al., 2022; IARC Vol 124, 2019).

  • Often saidShift work is a proven cause of breast cancer

    ActuallyThe classification is 'probable' (IARC Group 2A), not proven, and the breast-cancer link specifically is contested: a pooled analysis of 10 prospective studies and ~1.4 million women found a relative risk of 0.99, essentially no effect, while other pools and the Nurses' Health Study II show modest elevations. The honest statement is 'associated with, under active debate,' not 'causes' (Travis et al., JNCI 2016; IARC 2019).

  • Often saidThe cancer worry is the main shift-work health risk

    ActuallyThe most consistent and robust associations are cardiometabolic, not cancer: meta-analyses link shift work to coronary heart disease and myocardial infarction (relative risk near 1.2) and type 2 diabetes (near 1.1, rising with years worked). These signals are more reproducible across cohorts than the cancer findings (Vyas et al., BMJ 2012; Gan et al., 2018).

  • Often saidMelatonin or a pill fixes shift work

    ActuallySleep-medicine guidance offers only conditional recommendations, melatonin-receptor agonists for daytime sleep, timed bright light and modafinil or armodafinil for alertness, and these manage symptoms rather than removing the underlying circadian risk. Care should be individualized with a qualified provider (AASM shift-work-disorder guidance).

Who profits, and who pushes back

  • Dr. Charles Czeisler

    Promotes itHarvard Medical School

    Decades of occupational circadian research; argues shift-work health effects are seriously underappreciated. Academic.

  • Occupational-health researchers

    Promotes itAcademic

    Study scheduling, light, and countermeasures to reduce shift-work harm.

  • Ruth C. Travis and colleagues

    Pushes backCancer epidemiologists, University of Oxford; lead authors of the largest prospective breast-cancer pooling

    The authors concluded that 'the totality of the prospective evidence shows that night shift work, including long-term shift work, has little or no effect on breast cancer incidence,' and that the findings 'exclude a moderate association,' arguing the classification of shift work as a probable breast carcinogen 'is no longer justified' (Travis et al., JNCI 2016).

  • IARC mechanism and epidemiology reviewers

    Pushes backIARC Monographs Volume 124 working group (2019)

    The working group judged the human cancer evidence 'limited' while finding 'sufficient' evidence in animals and 'strong' mechanistic evidence, an unusual pattern in which experimental findings outweigh the human data, leaving the classification at 'probable' (Group 2A) rather than 'carcinogenic' (Group 1).

  • Chronobiology commentators (Erren and colleagues)

    Pushes backOccupational and circadian-medicine researchers

    They caution that defining the exposure narrowly as workplace 'night shift work' may misclassify the real driver, disturbed chronobiology that also occurs outside work, and warn against treating the 2A label as a precise causal verdict for individuals (commentary, PMC6882045, 2019).

Where the research comes from

Share of published research by country of origin.
PlaceShare of published research
Europe34%
USA32%
Asia20%
Other14%

Research published from: Global.

How we got here

Working through the night is ancient, lit first by oil lamps (stone lamps at Lascaux date back roughly 30,000 years) and later whale-oil and gas lamps. The decisive shift came when Thomas Edison electrified Manhattan's Pearl Street Station in 1882, removing the natural stop-signal of darkness and making round-the-clock factories economically viable across Europe and the Americas within a decade. The health framing is more recent. In 1987 Richard Stevens, then at Pacific Northwest Laboratories, proposed that electric light at night suppresses nocturnal melatonin and could raise breast-cancer risk, a hypothesis he mailed to Harvard's Walter Willett, whose group later reported elevated risk among night-working nurses. Large nurse cohorts through the 1990s and 2000s sharpened the question. In 2007 IARC first classified shift work involving circadian disruption as probably carcinogenic, and in 2009 Denmark became the first country to pay government compensation to women who developed breast cancer after long-term night work. IARC re-affirmed Group 2A in 2019.

  1. ~30,000 BCEStone oil lamps at Lascaux, France, evidence humans extended activity past dark long before electricity
  2. 1882Edison electrifies Pearl Street Station, New York; affordable electric light makes the 24-hour factory and night shift economically viable
  3. 1987Richard Stevens proposes the light-at-night hypothesis, that suppressed nocturnal melatonin could raise breast-cancer risk
  4. 1990s-2000sNurses' Health Study and other large cohorts link long-term night work to elevated breast-cancer and metabolic-disease risk
  5. 2007IARC first classifies shift work involving circadian disruption as Group 2A, probably carcinogenic to humans
  6. 2009Denmark becomes the first country to pay government compensation for breast cancer recognized as a night-work occupational injury
  7. 2012Vyas et al. BMJ meta-analysis links shift work to myocardial infarction and coronary events
  8. 2016Travis et al. JNCI pooled-prospective analysis (~1.4M women) finds little or no breast-cancer effect and challenges the IARC classification
  9. 2019IARC Volume 124 re-affirms Group 2A for night shift work: limited human, sufficient animal, strong mechanistic evidence
  10. 2020sShift Work Disorder management formalized in sleep-medicine clinical guidance; circadian-misalignment lab studies detail cardiometabolic mechanisms

At a glance

IARC class
2A probable carcinogen
Affects
~15-20% of workers
Linked to
Cancer, CVD, diabetes, depression
Breast cancer
+30-50% relative risk

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Shift Work. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources